Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage

Neurocrine Biosciences Inc. (NASDAQ:NBIX) on Monday shared data from its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who have dyskinetic cerebral palsy (DCP).Cerebral palsy (CP) is a nonprogressive neurodevelopmental disorder that affects movement and posture, starting in early childhood. It occurs in about three per 1,000 children in the United States.People living with dyskinetic cerebral palsy (DCP) often have mixed hyperki ...